Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Novel Drug Effectively Shrinks Tumors in Hodgkin Lymphoma
(Posted: 12/07/2010) - An investigational drug composed of a monoclonal antibody linked to a potent chemotherapy agent led to complete or substantial tumor shrinkage in nearly 40 percent of patients with Hodgkin lymphoma in a phase I clinical trial, researchers reported November 4, 2010, in the New England Journal of Medicine.
- Lasofoxifene Is Potential New Option for Breast Cancer Risk Reduction
(Posted: 12/07/2010) - An investigational agent in the same family of drugs as tamoxifen and raloxifene may be as or more effective in reducing breast cancer risk in some women. The drug, lasofoxifene, also appears to have important benefits for both bone and heart health and, with one exception, appears to lack the rare but potentially serious side effects associated with tamoxifen and raloxifene, according to results published November 4, 2010, in the Journal of the National Cancer Institute.
- Crizotinib Continues to Show Promise for Some Lung Tumors, Faces Challenge of Drug Resistance
(Posted: 12/07/2010) - New data from a phase I trial of crizotinib, a small-molecule drug that targets cancer-causing chromosomal rearrangements involving the gene ALK, in patients with non-small cell lung cancer add to positive results published October 28, 2010, in the New England Journal of Medicine.
- More Evidence Suggests Aspirin May Prevent Colorectal Cancer
(Posted: 12/07/2010) - A new meta-analysis shows that both colorectal cancer and deaths from the disease may be reduced by long-term daily use of aspirin, according to results published online October 21, 2010, in The Lancet.
- Romidepsin Reduces Disease Burden and Skin Symptoms in Patients with Previously Treated Cutaneous T-Cell Lymphoma
(Posted: 11/08/2010) - Clinical trial results published October 10, 2010, in The Journal of Clinical Oncology, show that romidepsin (Istodax®), a type of targeted therapy called a histone deacetylase inhibitor, reduced the symptoms and tumor burden of cutaneous T-cell lymphoma in many patients with advanced disease.